Antiangiogenic therapy: Not just for cancer anymore?
Vijay H. Shah, Jordi Bruix – 27 March 2009
Abrogation of hepatic ATP‐citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor‐deficient mice
Qiong Wang, Lei Jiang, Jue Wang, Shoufeng Li, Yue Yu, Jia You, Rong Zeng, Xiang Gao, Liangyou Rui, Wenjun Li, Yong Liu – 27 March 2009 – Hepatic steatosis is a hallmark of nonalcoholic fatty liver disease (NAFLD) and a key component of obesity‐associated metabolic dysfunctions featuring dyslipidemia, insulin resistance, and loss of glycemic control. It has yet to be completely understood how much dysregulated de novo lipogenesis contributes to the pathogenic development of hepatic steatosis and insulin resistance.
Hepatitis B surface antigen quantification as a current‐day paradox: Obtaining the gold in the face of diminishing returns
Robert P. Perrillo – 27 March 2009
Liver failure as initial presentation of autoimmune hepatitis: Clinical characteristics, predictors of response to steroid therapy, and outcomes
Sumita Verma, Anurag Maheshwari, Paul Thuluvath – 27 March 2009
A woman with chronic anemia and cholestatic liver disease
M. Isabel Fiel, Thomas Schiano – 27 March 2009
Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients
Rami Moucari, Vincent Mackiewicz, Olivier Lada, Marie‐Pierre Ripault, Corinne Castelnau, Michelle Martinot‐Peignoux, Agnes Dauvergne, Tarik Asselah, Nathalie Boyer, Pierre Bedossa, Dominique Valla, Michel Vidaud, Marie‐Hélène Nicolas‐Chanoine, Patrick Marcellin – 27 March 2009 – Pegylated interferon alfa‐2a (PEG‐IFN) may induce sustained virological response (SVR) in 20% of hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B (CHB) patients. In addition, loss of hepatitis B surface antigen (HBsAg) is achieved with a 10% yearly rate after treatment cessation in sustained responders.
A crossing in therapy for hepatitis C virus genotype 2 or 3: Increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration
Chung‐Feng Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu – 27 March 2009
A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature
Jean‐Louis Delaunay, Anne‐Marie Durand‐Schneider, Danièle Delautier, Alegna Rada, Julien Gautherot, Emmanuel Jacquemin, Tounsia Aït‐Slimane, Michèle Maurice – 27 March 2009 – Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare liver disease characterized by early onset of cholestasis that leads to cirrhosis and liver failure before adulthood. PFIC3 may be improved by chronic administration of ursodeoxycholic acid, although in many cases liver transplantation is the only therapy.
Diagnosis, management, and treatment of hepatitis C: An update
Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff – 27 March 2009
Diagnosis, management, and treatment of hepatitis C: An update
Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff – 27 March 2009